Hypertension accounts for about 50% of an individual's cardiovascular (CV) risk. 1 This risk has been attributed to not only the mean blood pressure (BP) load but also the variability of an individual's BP. 2 Over the last decades, evidence has been mounting that, in addition to the absolute BP values, high BP variability is associated with the development, progression, and severity of cardiac, cerebral, renal, and vascular damage, together with increased risk of CV mortality. 3,4 Severity of the hypertensive complications also depends on the other simultaneous CV risk factors associated with the target organ damage. Hyperhomocysteinemia (plasma homocysteine level ≥10 µmol/l) is regarded as one of the CV risk factors in Chinese hypertensive adults. 5 It is associated with atherosclerotic diseases, 6 particularly ischemic stroke in Chinese. 7 Although the effect of homocysteine-lowering intervention was still controversial, it seems dependent on the geography and ethnicity with the specific beneficial effect in low folate consumption area such as Asia. 8 Recently, homocysteinelowering intervention with folic acid therapy was actually convinced to significantly reduce the first stroke in adults with hypertension in China, independently of BP levels. 9 In the past few years, homocysteine level was reported to be associated with BP level not only in animal models but also in humans. 10-14 Interestingly, homocysteine-lowering intervention with folic acid therapy was recently shown to be able to decrease the nocturnal systolic BP (SBP) and thus increase the day-night difference of BP in healthy humans, 15 which indicated a potential relationship between homocysteine and circadian BP variation. In view of the clinical importance of the BP level, BP variation and homocysteine in hypertension, the relationship among the 3 factors deserves more attention in hypertensive adults, particularly in hypertensive adults combined with hyperhomocysteinemia. Therefore, in the present study, we have made an attempt to clarify the association between plasma total homocysteine level (tHcy) and circadian BP variation in Chinese hypertensive adults. 
METHODS

Subjects
We enrolled 244 eligible dipping and 249 eligible nondipping BP status adults from 560 adults who were randomly sampled from 5,233 hypertensive adults who received ambulatory BP monitoring (ABPM) at the Second Affiliated Hospital of Nanchang University, from March 2014 to April 2016. Of those eligible for participation, we excluded 67 subjects because of the subjects with missing covariate data (n = 46), incomplete medical records (n = 20), and measurement error (n = 1) (Supplementary Figure 1) . We further enrolled 390 hypertensive adults with CC/CT genotypes of the methylenetetrahydrofolate reductase (MTHFR) and 79 TT genotype who received ABPM at the same time from 1,858 hypertensive adults with MTHFR polymorphisms detection at our hospital from January 2016 to November 2016. Primary hypertension was defined as being received antihypertensive drugs or SBP ≥140 mm Hg and/or diastolic BP (DBP) ≥90 mm Hg (clinical BP). Exclusion criteria were secondary hypertension and severe systemic diseases as described previously. 16 All subjects underwent routine medical history, physical examination, and laboratory assessment. The study was approved by the Medical Research Ethics Committee of Second Affiliated Hospital of Nanchang University and a signed informed consent was obtained from each subject before participation.
Baseline assessments
The baseline assessments were performed as described previously. 17 Please see the detailed technical points in Online Supplemental Materials.
MTHFR polymorphisms detection
MTHFR C677T polymorphisms were detected on an ABI 7500 Real-Time PCR System (Life Technologies) using the TaqMan assay (AUSA, Shenzhen, China).
24-hour ABPM and dipping statuses classification
All subjects had good technical quality 24-hour ABPM with validated devices (Schiller Br-102 Plus Ambulatory BP Monitor). We classified the subtypes of nocturnal BP fall as follow: dipping (≥10% nocturnal decline in BP) and nondipping (<10% nocturnal decline in BP). 18 Please see the detailed technical points in Online Supplemental Materials.
Statistical analysis
Normally distributed data were expressed as mean ± SD. Nonnormally distributed results were expressed as the median value (interquartile or percentage range). Categorical values were presented as numbers (percentage). The study adults were stratified into 2 groups according to the extent of the nocturnal BP fall.
Differences between groups were evaluated using Independent-Samples T test or Mann-Whitney U-test as appropriate for the continuous variables, and the chi-square test for the categorical variables. Continuous variables with a skewed distribution were ln-transformed to attain normal distributions before correlation or regression analyses. Pearson's correlation was used for simple linear analysis between ln (tHcy) and ln (rate of nocturnal SBP fall) or ln (rate of nocturnal DBP fall), respectively. Multinomial logistic regression analysis was used to assess the graded association between tHcy tertiles (<11.3, 13.3-15.1, ≥15.1 µmol/l) and the rate of nocturnal SBP or DBP decline. Univariate and multivariate logistic regression analyses were used to assess the clinical factors correlated with the presence of nondipping BP status among hypertensive adults. A 2-sided P value of <0.05 was considered significant. We also used logistic regression analysis to examine the potential effects of the MTHFR C677T polymorphism on risk of nondipping BP status under 4 genetic models (homozygous codominant, heterozygous codominant, dominant, and recessive models). All statistical analyses were performed with SPSS software for Windows, version 16.0 (SPSS, Chicago, IL). Table 1 details the clinical characteristics of the study groups in the present study. A total of 493 hypertensive adults were finally included in the study comprising 244 dipping subjects and 249 nondipping subjects (Supplementary Figure 1) . Compared with the dippers, the nondippers were older, thinner, combined with more coronary heart diseases, and less hyperlipidemia. The nondippers were medicated with more angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, diuretics, beta-blockers, and less calcium-channel blockers. The nondippers had higher tHcy and lower levels of total cholesterol, triglyceride, and low-density lipoprotein cholesterol. Table 2 details the 24-hour, daytime, and nighttime ambulatory BP parameters of the subjects with dipping and nondipping BP statuses. The nondippers had a significantly higher nighttime mean SBP, DBP, and higher 24-hour and nighttime mean pulse pressure than the dippers. Compared with the dippers, the 24-hour and daytime mean SBP, DBP, and mean heart rates were significantly lower in the nondippers.
RESULTS
Clinical characteristics of study groups
ABPM data
Higher homocysteine level was associated with nondipping BP status in hypertensive adults Figure 1a showed that tHcy was significantly higher in nondippers than dippers (P < 0.001). Simple linear analysis revealed that ln (tHcy) was significantly correlated with ln (rate of nocturnal SBP fall) (r = −0.145, P = 0.001) (Figure 1b Table 1 ).
Supplementary Figure 2 showed that, in contrast to 36.54% of nondippers in subjects with normal tHcy (<10 µmol/l), 54.24% of nondippers was shown in subjects with high tHcy (≥10 µmol/l) (P = 0.001). Figure 2 showed the 24-hour BP circadian chronograms of subjects with normal tHcy (<10 µmol/l) and high tHcy (≥10 µmol/l). As shown in Figure 2a or b, a tendency of lower SBP or DBP was found in subjects with normal tHcy (<10 µmol/l) compared with subjects with high tHcy (≥10 µmol/l) during the nighttime (from 22:00 h to 6:59 h). Statistical significance was found at 2:00 h or 7:00 h (P < 0.05) for SBP and at 6:00 h or 7:00 h (P < 0.05) for DBP, respectively. Abbreviations: ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; eGFR, estimate glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. *P < 0.001, † P < 0.05 compared with dippers.
MTHFR polymorphisms. Figure 3a showed that the percentage of dipping BP status was 19.49% and the nondipping BP status was 80.51% in CC/CT genotypes. In contrast, the percentage of dipping BP status was 8.86% and the nondipping BP status was 91.14% in TT genotype (Figure 3b ). The percentage of BP status was significantly different between CC/CT and TT genotypes (P = 0.024). Figure 3c showed that tHcy was significantly higher in TT genotype than CC/CT genotypes (P < 0.001).
Association between MTHFR C677T polymorphism and nondipping BP status susceptibility Table 4 showed that associations of the MTHFR C677T polymorphism with nondipping BP status risk using the logistic regression analysis under four genetic models. In the univariate analysis, the MTHFR C677T polymorphism was significantly associated with nondipping BP status under the heterozygous recessive model (OR: 2.490, 95% CI: 1.102-5.627, P = 0.028). After adjustments for age and gender, significant association was still observed in heterozygous recessive model (OR: 2.507, 95% CI: 1.095-5.743, P = 0.030).
DISCUSSIONS
The major finding of the present study is that plasma tHcy level was associated with the BP variation in Chinese hypertensive adults. This finding was supported by the following results: (i) tHcy was significantly higher in nondippers than dippers ( Figure 1a) ; (ii) tHcy was significantly and negatively correlated with the percentage of nocturnal BP fall in hypertensive adults ( Figure 1b and c) ; (iii) tHcy was positively and independently correlated with the presence of nondipping BP status in hypertensive adults (Table 3) ; (iv) median and highest grading of tHcy associated with higher risk of disturbed nocturnal BP decline in hypertensive adults (Supplementary Table 1) ; (v) the rate of nondipping BP status was significantly higher in hypertensive adults with TT genotype than CC/CT genotypes ( Figure 3a and b) ; (vi) MTHFR C677T polymorphism was significantly associated with nondipping BP status under the heterozygous recessive model (Table 4) . These results may represent an important hypothesis, from the view of the circadian BP variation, that tHcy might be a therapeutic target for disturbed circadian BP variation in hypertensive adults with low folic acid consumption.
The association between hyperhomocysteinemia and increased BP level was previously demonstrated in experimental animals, 10, 11 as well as in humans. 13, 14 Interestingly, homocysteine-lowering intervention with folate administration was further shown to significantly decrease the nocturnal SBP, DBP, and mean BP 19 and significantly increase the day-night difference of mean and DBP in healthy postmenopausal women. 15 Although the mechanism is still unclear, the above studies indicated that tHcy was associated with not only the BP level but also possibly the circadian BP variation.
The findings in the present study expanded the current understanding of the relationship between tHcy and the circadian BP variation. Hyperhomocysteinemia has been demonstrated to associate with CV diseases, 20 especially the stroke. 7, 21 Stroke is currently the leading cause of death in China. 22 Although the clinical effectiveness of homocysteine-lowering intervention such as folic acid therapy is still controversial worldwide, 23 it was recently verified to be able to significantly reduce the risk of stroke in Chinese hypertensive adults, independently of BP levels. 9 Circadian BP variation could also provide substantial prognostic information in adults with hypertension, independently of 24-hour SBP levels. 24 Two prospective studies including over 2,000 Japanese revealed that the disturbed nocturnal decline in BP is associated with stroke. 25, 26 Moreover, the relation between disturbed circadian BP variation and stroke was also demonstrated in Chinese hypertensive adults. 27 Therefore, the comprehensive intervention of both tHcy and the disturbed circadian BP variation might be clinically important in hypertensive adults combined with hyperhomocysteinemia, especially in area where there is no folic acid fortification of food and the stroke incidence is high. MTHFR is a rate-limiting enzyme in the methyl cycle, and it is encoded by the MTHFR gene. 28 MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a substrate for homocysteine remethylation to methionine. The homozygous mutated subjects of MTHFR (TT genotype) have lower MTHFR activity than the heterozygous mutated or the normal, nonmutated subjects (CC/CT genotypes), and thus have higher homocysteine levels than CC/CT genotypes. 29 MTHFR 677C→T polymorphism has been associated with raised homocysteine concentration and increased risk of various diseases with the epidemiology of the polymorphism of the C677T that varies dependent on the geography and ethnicity. 8, 30 The genetic meta-analysis revealed that the OR for stroke was 1.26 (1.14-1.40) for TT vs. CC genotype, which was similar to the expected OR from the differences in homocysteine concentration based on observational studies. 31 The OR (1.55, 1.26-1.90) from the genetic studies for ischemic stroke was even higher in Chinese population. 32 These results indicate the causal relation between tHcy and stroke. In the present study, tHcy was significantly higher in hypertensive adults with TT genotype than CC/CT genotypes (Figure 3c) . Interesting, the percentage of nondipping status was significantly higher in hypertensive adults with TT genotype than CC/CT genotypes (Figure 3a and b) . Of note, this result corresponded to a significantly higher tHcy in nondippers compared with dippers ( Figure 1a ). Although our results could not provide the direct evidence for a causal role of tHcy in the pathogenesis of the blunted nocturnal BP fall in the hypertensives, this concordance nevertheless rationalized the future prospective studies to explore the causal relationship between tHcy and circadian BP variation.
The present study has certain limitations. Firstly, our study is a cross-sectional design, and future prospective study is warranted to explore the causal relationship between tHcy and circadian BP variation. Secondly, the values of BP level and variability probably influenced to an extent by doses and use time of medications. Thirdly, dietary history and folic acid intake information were not collected and that might affect tHcy in subjects in the present study. In addition, the study investigated the subjects in a single center and with ABPM lasting for only 24 hours. The mechanism underlying the correlation of tHcy and BP dipping status in the hypertensive adults is still unknown. Lower levels of triglyceride and total cholesterol were shown to associate with the presence of nondipping status in the present study. Currently, we have no ideas to explain such an association and more investigation are needed to clarify this issue in future. Despite these limitations, however, this study provided the evidence for the relationship between tHcy and circadian BP variation Taken together, this is the first study, to the best of our knowledge, showed an association between tHcy and circadian BP variation in hypertensive adults. This finding may extend our current understanding of the relationship between tHcy and BP from the BP level to circadian BP variation in hypertension and may bring the light to a new target for intervention of disturbed circadian BP variation in hypertension.
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